Verve Therapeutics, Inc.

NasdaqGS:VERV Stock Report

Market Cap: US$501.8m

Verve Therapeutics Valuation

Is VERV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VERV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VERV's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VERV's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for VERV?

Other financial metrics that can be useful for relative valuation.

VERV key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does VERV's PS Ratio compare to its peers?

The above table shows the PS ratio for VERV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average31.1x
TRDA Entrada Therapeutics
2.6x-78.5%US$619.3m
IMNM Immunome
65x60.1%US$701.0m
CAPR Capricor Therapeutics
32.6x48.1%US$884.3m
TSHA Taysha Gene Therapies
24.4x51.8%US$313.6m
VERV Verve Therapeutics
24.3x-13.6%US$501.8m

Price-To-Sales vs Peers: VERV is good value based on its Price-To-Sales Ratio (24.3x) compared to the peer average (31.1x).


Price to Earnings Ratio vs Industry

How does VERV's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a27.1%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a27.1%
n/an/an/a
No more companies

Price-To-Sales vs Industry: VERV is expensive based on its Price-To-Sales Ratio (24.3x) compared to the US Biotechs industry average (12.6x).


Price to Sales Ratio vs Fair Ratio

What is VERV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VERV PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio24.3x
Fair PS Ratio0.004x

Price-To-Sales vs Fair Ratio: VERV is expensive based on its Price-To-Sales Ratio (24.3x) compared to the estimated Fair Price-To-Sales Ratio (0x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VERV forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$5.93
US$26.01
+338.6%
28.2%US$40.00US$15.00n/a10
Oct ’25US$4.79
US$26.01
+443.0%
28.2%US$40.00US$15.00n/a10
Sep ’25US$6.70
US$26.01
+288.2%
28.2%US$40.00US$15.00n/a10
Aug ’25US$6.73
US$25.78
+283.0%
27.2%US$40.00US$15.00n/a9
Jul ’25US$4.98
US$26.89
+439.9%
28.2%US$40.00US$15.00n/a9
Jun ’25US$5.19
US$26.89
+418.1%
28.2%US$40.00US$15.00n/a9
May ’25US$6.00
US$31.22
+420.4%
35.1%US$55.00US$15.00n/a9
Apr ’25US$12.79
US$48.25
+277.2%
33.0%US$75.00US$24.00n/a8
Mar ’25US$16.29
US$48.25
+196.2%
33.0%US$75.00US$24.00n/a8
Feb ’25US$11.21
US$45.89
+309.4%
36.0%US$75.00US$22.00n/a9
Jan ’25US$13.94
US$45.89
+229.2%
36.0%US$75.00US$22.00n/a9
Dec ’24US$11.79
US$46.44
+293.9%
34.3%US$75.00US$22.00n/a9
Nov ’24US$11.75
US$46.11
+292.4%
35.3%US$75.00US$22.00US$5.939
Oct ’24US$13.26
US$46.11
+247.7%
35.3%US$75.00US$22.00US$4.799
Sep ’24US$13.45
US$41.73
+210.2%
42.7%US$75.00US$13.00US$6.7011
Aug ’24US$19.42
US$42.00
+116.3%
42.4%US$75.00US$13.00US$6.7311
Jul ’24US$18.75
US$42.00
+124.0%
42.4%US$75.00US$13.00US$4.9811
Jun ’24US$15.41
US$41.82
+171.4%
43.1%US$75.00US$13.00US$5.1911
May ’24US$16.04
US$42.27
+163.5%
41.7%US$75.00US$14.00US$6.0011
Apr ’24US$14.42
US$42.60
+195.4%
41.3%US$75.00US$14.00US$12.7910
Mar ’24US$18.19
US$42.40
+133.1%
41.4%US$75.00US$13.00US$16.2910
Feb ’24US$22.07
US$42.40
+92.1%
41.4%US$75.00US$13.00US$11.2110
Jan ’24US$19.35
US$44.78
+131.4%
37.7%US$75.00US$13.00US$13.949
Dec ’23US$22.57
US$49.50
+119.3%
28.1%US$75.00US$35.00US$11.798
Nov ’23US$36.44
US$53.13
+45.8%
21.3%US$75.00US$36.00US$11.758

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies